Oscotec Inc Market Cap ($674.16 Million)
Market Cap & Net Worth: Oscotec Inc (039200)
Oscotec Inc market cap. Oscotec Inc (KQ:039200) has a market capitalization of $674.16 Million (₩994.80 Billion) as of November 4, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #10371 globally and #269 in its home market, demonstrating a -1.67% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oscotec Inc's stock price ₩35400.00 by its total outstanding shares 28101800 (28.10 Million). Also see Oscotec Inc (039200) cash conversion ratio for how efficiently the company converts equity into cash flow.
Oscotec Inc Market Cap History (2015–2026)
Oscotec Inc market cap history from 2015 to 2026. Data shows growth from $128.46 Million to $674.16 Million (19.21% CAGR). Check 039200 stock price and chart for real-time trading data and today's change.
Index Memberships
Oscotec Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$203.83 Billion | 0.33% | #57 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$203.83 Billion | 0.33% | #57 of 1384 |
Weight: Oscotec Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Oscotec Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oscotec Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Oscotec Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.01x
Oscotec Inc's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.02x
Oscotec Inc's market cap is 0.02 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $131.21 Million | $3.55 Billion | -$3.65 Billion | 0.04x | N/A |
| 2017 | $301.88 Million | $3.91 Billion | -$3.89 Billion | 0.08x | N/A |
| 2018 | $414.74 Million | $18.70 Billion | $3.47 Billion | 0.02x | 0.12x |
| 2019 | $442.27 Million | $4.37 Billion | -$22.44 Billion | 0.10x | N/A |
| 2020 | $1.20 Billion | $43.47 Billion | -$4.36 Billion | 0.03x | N/A |
| 2021 | $671.66 Million | $3.90 Billion | -$26.26 Billion | 0.17x | N/A |
| 2022 | $329.46 Million | $5.06 Billion | -$24.43 Billion | 0.07x | N/A |
| 2023 | $438.97 Million | $4.95 Billion | -$24.28 Billion | 0.09x | N/A |
| 2024 | $463.73 Million | $34.01 Billion | $876.53 Million | 0.01x | 0.53x |
| 2025 | $860.80 Million | $99.84 Billion | $52.34 Billion | 0.01x | 0.02x |
Competitor Companies of 039200 by Market Capitalization
Companies near Oscotec Inc in the global market cap rankings as of November 4, 2026. Also see Oscotec Inc total assets for a full breakdown of the balance sheet.
Key companies related to Oscotec Inc by market ranking:
- Sam Chun Dang Pharm. Co. Ltd (KQ:000250): Ranked #5272 globally with a market cap of $2.49 Billion USD ( ₩3.67 Trillion KRW).
- ST Pharm Co.Ltd (KQ:237690): Ranked #8989 globally with a market cap of $902.70 Million USD ( ₩1.33 Trillion KRW).
- Komipharm International Co. Ltd (KQ:041960): Ranked #13842 globally with a market cap of $343.99 Million USD ( ₩507.59 Billion KRW).
- Mezzion Pharma Co.Ltd (KQ:140410): Ranked #14696 globally with a market cap of $289.01 Million USD ( ₩426.46 Billion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #5272 | Sam Chun Dang Pharm. Co. Ltd | KQ:000250 | $2.49 Billion | ₩171400.00 |
| #8989 | ST Pharm Co.Ltd | KQ:237690 | $902.70 Million | ₩71400.00 |
| #13842 | Komipharm International Co. Ltd | KQ:041960 | $343.99 Million | ₩8780.00 |
| #14696 | Mezzion Pharma Co.Ltd | KQ:140410 | $289.01 Million | ₩49900.00 |
Market Capitalization of Oscotec Inc (2015–2026)
Market capitalization of Oscotec Inc from 2015 to today. Between 2015 and today, Oscotec Inc's market cap moved from $128.46 Million to $ 674.16 Million, with a yearly change of 19.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩674.16 Million | -21.68% |
| 2025 | ₩860.80 Million | +85.63% |
| 2024 | ₩463.73 Million | +5.64% |
| 2023 | ₩438.97 Million | +33.24% |
| 2022 | ₩329.46 Million | -50.95% |
| 2021 | ₩671.66 Million | -44.21% |
| 2020 | ₩1.20 Billion | +172.20% |
| 2019 | ₩442.27 Million | +6.64% |
| 2018 | ₩414.74 Million | +37.39% |
| 2017 | ₩301.88 Million | +130.07% |
| 2016 | ₩131.21 Million | +2.14% |
| 2015 | ₩128.46 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Oscotec Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $674.16 Million USD |
| MoneyControl | $674.16 Million USD |
| MarketWatch | $674.16 Million USD |
| marketcap.company | $674.16 Million USD |
| Reuters | $674.16 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Oscotec Inc
Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody… Read more